Help put new drug for advanced prostate cancer on the PBS

Prostate Cancer Foundation of Australia is encouraging our Support Group, Ambassador and supporter networks to participate in consumer representation to the Pharmaceutical Benefits Advisory Committee (PBAC) re the drug Abiraterone Acetate (Zytiga) to be listed as part of the Pharmaceutical Benefits Scheme (PBS).

Men with metastatic prostate cancer that is resistant to androgen deprivation and who have failed docetaxel chemotherapy have a reduced life expectancy. For these men and their families the benefit that abiraterone acetate is taken orally and has low toxicity provides improved quality of life, particularly in the later stages of the disease.  Results from the clinical trial published in New England Journal of Medicine1 reported that side effects of abiraterone acetate were easily manageable and reversible.

Currently, this drug costs $36,000 a year. Availability on the PBS will increase access for men and their families.

Consumer comment closes on the 10th October, 2012. Comment can be made via an on-line form, or hard copy format. The form can be accessed at:

You can also access the forms and other helpful information, forums and supportive care for advanced prostate cancer through

For information on how to make a submission to PBAC click here

Please feel free to forward these links to people you know who may be interested in making comment. Men and members of their family and friends can provide individual comment.

^ top